| Old Articles: <Older 6461-6470 Newer> |
|---|
 |
BusinessWeek
July 15, 2010
Palmeri & Marois |
The Latest Fiscal Buzz? Medical Marijuana Cities are taxing marijuana dispensaries to trim budget deficits.   |
Chemistry World
July 15, 2010
Matt Wilkinson |
Biotechs plot path of least resistance Biopharmaceutical companies are moving into antibiotics, and filling the void left by big pharma. |
The Motley Fool
July 15, 2010
Brian Orelli |
The Blockbuster Drug Survives Another Body Blow Avandia is still standing. |
The Motley Fool
July 15, 2010
Ryan McBride |
Glaxo's Tempero Pharma Advances on Hot Niche of Immunology Staking claim in emerging fields. |
The Motley Fool
July 14, 2010
Luke Timmerman |
Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug |
The Motley Fool
July 13, 2010
Brian Orelli |
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. |
The Motley Fool
July 12, 2010
Brian Orelli |
Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
July 9, 2010
Brian Orelli |
2 Days, 1 Blockbuster, Fate Unknown GlaxoSmithKline heads before a marathon two-day Food and Drug Administration advisory panel review of its diabetes drug Avandia. |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
| <Older 6461-6470 Newer> Return to current articles. |
